Carregant...

Golimumab pharmacokinetics in ulcerative colitis: a literature review

Golimumab (GLM) is the latest anti-tumor necrosis factor (TNF) that gained its marketing license. Thanks to the PURSUIT induction and maintenance trials, it was approved for the treatment of ulcerative colitis (UC) in 2013. The other anti-TNF drugs available are infliximab and adalimumab. These two...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Therap Adv Gastroenterol
Autors principals: Harzallah, Ines, Rigaill, Josselin, Williet, Nicolas, Paul, Stephane, Roblin, Xavier
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5330616/
https://ncbi.nlm.nih.gov/pubmed/28286562
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756283X16676194
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!